Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CAT | P04040 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29054677 | 0.86 | KDM4E (0.44) | ALDH1A1NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL30507841 | 0.86 | KDM4E (0.44) | ALDH1A1NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL30507834 | 0.83 | NPC1 (0.43) | ALDH1A1NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL29054687 | 0.83 | NPC1 (0.43) | ALDH1A1NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL30843242 | 0.80 | RAB9A (0.46) | NPC1RAB9ATP53SMN1; SMN2HTT | |
| SCHEMBL30843235 | 0.80 | KDM4E (0.43) | ALDH1A1MAPK1NPC1RAB9ATP53 | |
| SCHEMBL4489374 | 0.80 | KDM4E (0.43) | ALDH1A1MAPK1NPC1RAB9ATP53 | |
| SCHEMBL9489186 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MAPK1SRD5A2NPC1RAB9A | |
| SCHEMBL423788 | 0.79 | AOC3 (0.49) | ALDH1A1MAPK1SRD5A2NPC1RAB9A | |
| SCHEMBL6996541 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MAPK1SRD5A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106232595-B | Diaminotriazine compounds as herbicides | 巴斯夫欧洲公司 | 2020-01-14 | — | — | CN | disclosed |
| EP-3134400-B1 | DIAMINOTRIAZINE COMPOUNDS AS HERBICIDES | BASF SE (DE) | 2018-10-17 | — | — | EP | disclosed |
| US-9822105-B2 | Diaminotriazine compounds as herbicides | BASF SE (DE) | 2017-11-21 | — | — | US | disclosed |
| EP-3134400-A1 | DIAMINOTRIAZINE COMPOUNDS AS HERBICIDES | BASF SE (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-20170050954-A1 | Diaminotriazine Compounds as Herbicides | BASF SE (DE) | 2017-02-23 | — | — | US | disclosed |
| WO-2015162169-A1 | DIAMINOTRIAZINE COMPOUNDS AS HERBICIDES | BASF SE (DE) | 2015-10-29 | — | — | WO | disclosed |
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| EP-1409481-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | disclosed |
| EP-1409481-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003047582-A1 | QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ABL1, FLT3, JAK2 | ALDH1A1 3215/4885MAPK1 67/4885SRD5A2 4704/4885 |
| US-20170050954-A1 | Diaminotriazine Compounds as Herbicides | NR4A3, RXRB, CBR3 | ALDH1A1 647/4885MAPK1 2794/4885SRD5A2 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.